Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TREATMENT WITH FINASTERIDE FOLLOWING RADICAL PROSTATECTOMY FOR PROSTATE-CANCER
Autore:
ANDRIOLE G; LIEBER M; SMITH J; SOLOWAY M; SCHROEDER F; KADMON D; DEKERNION J; RAJFER J; BOAKE R; CRAWFORD D; RAMSEY E; PERREAULT J; TRACHTENBERG J; FRADET T; BLOCK N; MIDDLETON R; NG J; FERGUSON D; GORMLEY G;
Indirizzi:
MERCK & CO INC,RES LABS,POB 2000 RAHWAY NJ 07065 MERCK & CO INC,RES LABS RAHWAY NJ 07065 WASHINGTON UNIV,SCH MED ST LOUIS MO 00000 MAYO CLIN & MAYO FDN ROCHESTER MN 55905 VANDERBILT UNIV NASHVILLE TN 00000 UNIV MIAMI MIAMI FL 33152 ERASMUS UNIV ROTTERDAM ROTTERDAM NETHERLANDS BAYLOR COLL MED HOUSTON TX 77030 UNIV CALIF LOS ANGELES,SCH MED LOS ANGELES CA 00000 UNIV CALIF LOS ANGELES,MED CTR LOS ANGELES CA 90024 UNIV ALBERTA EDMONTON AB CANADA UNIV COLORADO DENVER CO 80202 UNIV MANITOBA WINNIPEG MB R3T 2N2 CANADA HOP ST LUC MONTREAL PQ CANADA TORONTO GEN HOSP TORONTO ON CANADA UNIV LAVAL QUEBEC CITY PQ G1K 7P4 CANADA UNIV UTAH,MED CTR SALT LAKE CITY UT 00000
Titolo Testata:
Urology
fascicolo: 3, volume: 45, anno: 1995,
pagine: 491 - 497
SICI:
0090-4295(1995)45:3<491:TWFFRP>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOCAL RECURRENCE; ANTIGEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
16
Recensione:
Indirizzi per estratti:
Citazione:
G. Andriole et al., "TREATMENT WITH FINASTERIDE FOLLOWING RADICAL PROSTATECTOMY FOR PROSTATE-CANCER", Urology, 45(3), 1995, pp. 491-497

Abstract

Objectives, The objective of this study was to evaluate the effect offinasteride (10 mg/d) or placebo on serum prostate-specific antigen (PSA) and recurrence rates in men with detectable PSA levels after radical prostatectomy. Methods. A total of 120 men, 48 to 89 years old, previously treated with radical prostatectomy for prostate cancer withinthe past 10 years, with serum PSA levels between 0.6 and 10.0 ng/mL, with no evidence of skeletal metastasis on bone scan, and with no previous androgen deprivation therapy, were treated with 10 mg finasterideor placebo in a double-blind fashion for 12 months. After the first year, all patients were treated with finasteride for an additional 12 months. Primary endpoints were serum PSA levels and recurrence rates defined as positive bone scan or positive biopsy. Results. Patients treated with finasteride had a delayed increase in serum PSA compared withplacebo of approximately 9 months in the first year and 14 months by the end of the second year. Patients with baseline PSA levels less then 1.0 ng/mL had no significant increase in serum PSA during the 2 years of treatment. Fewer recurrences were observed in the finasteride group, but these differences were not statistically significant. Finasteride was well tolerated, and side effects were balanced between treatment groups. Conclusions. The results of this study indicate that treatment with finasteride delays but does not prevent the rise in serum PSAobserved in untreated patients with detectable PSA levels after radical prostatectomy. The reduction in local and distant recurrences in the finasteride group suggests that the effect on PSA reflects a direct effect on tumor growth without affecting the initial response to subsequent hormonal therapy. These data require confirmation by studies that are longer and larger, focused on demonstrating significant differences in progression rates and survival before the use of finasteride can be considered as an option for men with detectable PSA levels after radical prostatectomy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 00:56:28